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ABSTRACT cell regulation of Ph+cell proliferation and differentiation has been studied ex vivo in various chronic myeloid leukemia (cML) patients. the regulation 
is provided by alternation of effective stages of proliferation and maturation with inhibition of Ph+ cell proliferation by accumulating neutrophils under apoptosis 
blockage. the alternation of stages consists of switching stage 1 (effective proliferation) to stage 2 (effective maturation) and proceeds according to the 1/2 -1/2/1 
or 2/1-2/1/2/1 schemes. the kinetic plots of alternations pass through control points of crossing plots, where the parameters of proliferation and maturation are 
equal. the indices of P/D efficiency (ratio of proliferation and maturation rates) are 1.06±0.23 and don’t depend on time, alternation order, or sources of Ph+ cells 
– cML patients. During stages alternation, conversely, the parameters of Ph+ cell proliferation and maturation vary. the proliferation stages are characterized 
by increased proliferating cells content, a decreased number of neutrophils, and apoptosis induction. At the maturation stages, conversely, apoptosis is inhibited, 
the number of mature neutrophils increases, while immature Ph+ cells decrease. High content neutrophils inhibit the proliferation of Ph+ cells and impair their 
own maturation by inversion of maturation order, probably through a feedback mechanism. the regulation differences ex vivo reveal three types of Ph+ cells from 
various individual cML patients, distinguished by the number and duration of alternating stages of proliferation and maturation. Ph+ cells types 1 and 2 have one 
prolonged stage of effective proliferation or effective maturation with efficiency indices P/D1 = 1-20 or P/D2 ≤ 1. At the same time period, the proliferation and dif-
ferentiation of the Ph+ cells type 3 proceeds with repeated alternations of stages with P/D1 = 1-4 or P/D2 ≤ 1. type 1 Ph+ cells (~20%) were isolated from patients in 
advanced stages of cML, while Ph+ cells types 2 and 3 (30 and 50% correspondingly) were isolated from cML chronic phase patients sensitive to chemotherapy.
Keywords: regulation of Ph+cell proliferation and Ph+cell by mature cells, cultivation of hematopoietic Ph+ mononuclear cells, kinetics of Ph+cell proliferation and 
differentiation in vitro, Ph+cells apoptosis, Ph+cell distribution in cell cycle phases, Ph+cell proliferation and differentiation efficacy, inversion of accumulation 
order for maturating neutrophils, chronic myeloid leukemia.
Abbreviations: P&D – proliferation and differentiation; cML – chronic myeloid leukemia; Ph – Philadelphia chromosome; MM, B, S, – metamyelocytes, band and 
segmented neutrophils; Ph+cells – hematopoietic cells with Philadelphia chromosome; PB – peripheral blood ; BM – bone marrow; cP, AP, BP – chronic phase, 
accelerated phase and blastic phase of cML; FcS – fetal calf serum.
INTRODuCTION
Leukemias accounts for 1% of all deaths and 4-10% of deaths 
from cancer. the prevalence of leukemias and lymphomas 
varies from 3 to 9:100 000, depending on the geographical 
region. unfavorable radiation and ecological environment can 
increase it by 1.5 logs. In the u.S., leukemias are the major 
reason of death in children before 15.
the majority of leukemias result from genetic disturbanc-
es: chromosomal aberrations, translocations, inversions, dele-
tions, and various mutations [1-3, 6].
Philadelphia-positive (Ph+) cells, expressing active ty-
rosine kinase р210 or р185 (oncoproteins, products of bcr/
abl gene), are involved in chronic myeloid leukemia (cML) 
pathogenesis. It results in reciprocal chromosomal translo-
cation t(9;22)(q34;q11) in the polipotent hematopoietic stem 
cell. Proliferation and differentiation of this cell leads to re-
placement of normal hematopoietic cells by their monoclonal 
neoplastic Ph+ counterparts, thus promoting the development 
and progress of cML [1- 8, 10,12].
the cML clinical course varies among different patients. 
the cellular and molecular mechanisms of these differences 
remain unclear. current knowledge of cML course and pro-
gression in vivo is based upon analyses of averaged values 
of various parameters obtained at different moments and 
cML phases. cML undergoes a chronic phase (cP), acceler-
ated phase (AP), and an acute rapidly progressing blast phase 
(BP) with an inevitable fatal outcome. current cML therapy 
is based upon highly specific targeted drugs, tyrosine kinase 
inhibitors (tKI), specifically blocking р210 – imatinib and its 
analogues. Imatinib allows to extend life by 6 years in 88% of 
patients., of which 66% continue treatment. In 14% of those 
patients, cML progresses, while 5% of them interrupt treat-
ment because of toxicity. the toxicity is associated with ad-
ditional bcr/abl gene mutations, leading to therapeutic resist-
ance. Despite the development of a new generation of tKIs, 
the problem remains unsolved, because none of them kills the 
resting leukemia stem cells. Fewer than 5% of cML chronic 
phase patients are cured, while the majority eventually re-
lapse [6]. there is a need for another strategy in dealing with 
leukemia stem cells.
Despite the extensive research of Ph+ cells both in cultures 
and in vivo [4, 5, 7-12, 15-20,23,27], the processes taking place reSeArcH ArtIcLeS
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in the cells of newly diagnosed cML patients and in those in 
progression remain poorly studied. there is no unified con-
ception of the biological and molecular processes underway 
in cML both in vitro and in vivo and their interaction. Little is 
known about the patterns of proliferation and differentiation 
(P&D) of Ph+ cells even in vitro.
researchers have often noted that the cellular processes 
in cells isolated from cML patients differ from those in cell 
lines. the number of proliferating hematopoietic progeni-
tors in cML is decreased, while the number of nondividing 
mature neutrophils is higher than in normal cells [13,14,20-
23,26]. Ph+ stem cells proliferate less actively than healthy 
donor stem cells, while more differentiated Ph+ cells are ac-
cumulating more actively [20, 23, 24, 27]. this leads to sug-
gest that the cause of cML is the imbalance between stem 
cells self-renewal and myeloid progenitors maturation, 
rather than Ph+ cells proliferation under the action of р210 
bcr/ abl , as follows from many other studies [4-7,10-12, 15, 16, 
19, 24-29, 31].
It should be mentioned that the question of apoptosis block 
in Ph+ cells is also not obvious. evidently, our knowledge of 
cellular and molecular regulation of Ph+ cells in cML is still 
incomplete, though the oncogenic potential of bcr/abl onco-
gene, including enhanced cell viability, proliferation activa-
tion, and resistance to apoptosis, is studied in details in vari-
ous studies [7, 4,17,18, 25-27, 29, 30, 35 ,43-45].
the influence of different р210 mutations on proliferation, 
apoptosis, and the malignant properties of Ph+ cells trans-
fected with different bcr/abl mutated variants was studied 
in [27]. the activation of proliferation and apoptosis inhibition 
by p210 was shown to be independent processes closely linked 
to different bcr/abl mutations (including those responsible 
for intracellular signaling via various StAt proteins). It was 
hypothesized that those mutations can influence the sever-
ity of proliferation activation and apoptosis inhibition and 
shift their relative impact. In Ph+ cells of cML patients, these 
properties are not studied due to lack of suitable models and 
experimental approaches, though the bcr/abl mutations are 
actively studied and used in practice for cML diagnosis and 
treatment optimization [19, 29, 30-32]. Based on these con-
siderations, we have suggested that the kinetics of Ph+ cells 
P&D can reveal the differences in Ph+ cells P&D regulation 
of individual patients ex vivo.
the goal of our study was to clarify the mechanism of 
Ph+ cells P&D in individual cML patients ex vivo in suspen-
sion cultures by means of the previously developed kinetic 
method of study [33, 39]. the pattern of cML cells prolif-
eration and differentiation in cultures is similar to that of 
enhanced myelopoiesis in cML in vivo, allowing to estimate 
the efficiency of P&D, influence of growth factors, and the 
expression of bcr/abl and differentiation antigens in Ph+ 
cells.
MATERIALS AND METHODS
Materials: heparin (Flow, uK); Limphoprep, alpha-MeM me-
dia (MP Biomedical, uSA); DePc, Hepes, tris, PBS, fetal bo-
vine serum (FBS), sodium citrate, laurilsarcosyl (Icn, uSA); 
trypan blue stain, L-glutamine and 2-mercaptoethanol (Ser-
va, Germany), penicillin and streptomycin (OAO “Biochimik” 
Saransk russia); G-cSF (F.Hoffmann-La roche Ltd, France); 
tabletted PBS (10 mM phosphate buffer+ 0,13 M nacl + 2,7 
mM Kcl, pH 7,4), nPZ “eKO-servise” russia.
Ph+ mononuclear cells used for the study were prepared 
from the peripheral blood (PB) or bone marrow (BM) of cML 
patients in chronic phase (cP), accelerated phase (AP), and 
blastic phase (BP) before or under treatment. Leucocytes and 
granulocytes are the main cML mononuclears content; name-
ly, they have been investigated here. characteristics of Ph+ 
cells and cML patients from whose PB and BM the mono-
nuclears were isolated are given in tables 1-3. In  Ph+cells, 
bcr/abl rnA types as b3a2, b2a2, or e1a2 were assayed by 
rt-Pcr (reverse transcription-polymerase chain reaction) 
according to [33, 35].
Ph+ mononuclear cells were isolated from 10–15 ml of PB 
or 1-2 ml of BM aspirate (from superior iliac crest) of cML 
patients at different phases of the disease. the heparinized 
(50 Iu/ml) material was centrifuged for 30 min at 1500 rpm 
over Phycoll or Lymphoprep (1.077 or 1.119 g/sm3). the re-
sulted light fraction was washed twice with PBS at pH 6.8 
and once with a α-MeM media and then re-suspended in 
α-MeM media for analysis and cell cultivation. this fraction 
contained progenitor cells (blasts), lymphocytes, granulo-
cytes, and monocytes, as well as some quantities of mature 
neutrophils, typical for cML mononuclear cells. the viable 
and dead cell number was counted 3 times in smears, stained 
by 0.2% trypan blue according to romanovsky, with conse-
quent cell counting in Goryaev’s chamber.
Ph+ cells cultivation was performed according to [33]. cell 
suspension of 2÷8·106 cells/ml was incubated with α-MeM 
media containing 10-20% fetal calf serum (FcS, 2 mM L-
glutamine, 10-4 M 2-mercaptoethanol, 100 u/ml penicillin 
and 50 u/ml streptomycin, 25 mM HePeS-naOH, pH 7.2-7.4 
in 25 sm2 plastic flask for 2-3 h) nonadherent cells were then 
centrifuged at 1500 rpm for 7 min and re-suspended with the 
same medium to 0.8÷1.4·106 cells/ml and transferred to 24- 
or 96-well plates (12 wells per probe) and incubated at 37 0С 
with 100% humidity and 5% СО2 without FcS for 2 h. then 
10-20% of FcS was added, and the cells were cultured for 
6-14 days, selecting each sample from separate probes. every 
point was tested in triplex. Ph+ cells in the collected samples 
were washed from FcS by centrifuging in α-MeM media and 
analyzed for their morphology, cellular composition, distribu-
tion in the cell cycle phases, and apoptosis. We had separately 
determined that 2-hour incubation of cells without FcS with 
consequent incubation with FcS diminishes cell proliferation 
during the next ~6 hours. After that, the proliferation rate is 
restored, and 12 hours later the cellular composition becomes 
the same as in the cultures with FcS.
the prepared probes were analyzed for the number of vi-
able and dead cells and cell morphology in 3 zones of smear 
(100 cells in each) according to romanovsky, the individual 
cell morphology was identified according to Abramov [34], 
and we also calculated the percentage of each cell type in 
every sample. We calculated cell concentration in samples 
in 106 cells/ml and obtained plots for the kinetic curves of 
accumulation and depletion of different Ph+ cells and their 
subpopulations: proliferating cells (blasts, promyelocytes 
and myelocytes) – P and nondividing mature neutrophils: 
MM, B and S (metamyelocytes, band and segmented neu-
trophils) – D. the plots reflected the rate of production (or 110 | ActA nAturAe |  № 3 2009
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accumulation) of each differentiating cell type, transforming 
to the next subpopulation for this cell differentiation line. the 
mean error was ±5 ÷ 11%. We also studied apoptosis and cell 
cycle phase distribution by flow cytometry.
Ph-chromosome in PB and BM cells of our patients was 
identified cytogenetically (for 100 mitoses) or by FISH in the 
cytogenetical laboratory of the national research center for 
Hematology.
Flow cytometry for the analysis of the cell cycle phase 
distribution of the cultured Ph+cells selected during the 
incubation of Ph+ cells samples (5,000 cells each) after the 
isolation in Phycoll gradient were centrifuged for 7 min at 
2000 rpm and 4оС, washed with PBS, and accurately fixed 
by cold 70% ethanol for 30 min at 4оС. Before measurement, 
the suspension was washed with PBS, centrifuged, and the 
pellet was incubated in 0.5 ml of PBS containing 5 mcg/ml 
of propidium iodide and 50 mcg/ml of ribonuclease A for 30 
min at room temperature in a dark place [36, 37]. the cell 
measurements were done with flow cytometer ePIcS-XL. 
Сells of granulocytes gate were analyzed by direct (FSc) 
and side (SSc) light scatter with simultaneous registration 
of the FL2 fluorescence by amplitude and impulse square 
(it allows to exclude aggregated cells, conglomerates, and 
debris) in the linear and logarithmic scales. Simultaneously 
apoptotic cells are detected. FL2-H particles with hypodip-
loid DnA located as a separate peak leftward of the peak of 
diploid cells (decrease of cell size not more than by 2 logs) 
were considered to be apoptotic. the percentage of apoptot-
ic granulocytes was estimated within the granulocytic gate, 
where there is no cell debris. the DnA histograms from the 
same cell samples were analyzed for cell cycle phase distri-
bution (S, G2/M). Its analysis was done with the help of pre-
viously developed specialized software. It was based upon 
an algorithm developed for asynchronous proliferating cell 
populations (SFIt-method) [38].
the kinetic plots of Ph+ leucocytes (number increase and 
death of Ph+ cells) were obtained using the percentage of vi-
able and dead cells (see above) measured in 106 cells/ml. the 
proliferation rate of leucocytes in whole and granulocytes in 
particular was estimated from the kinetic plots of its accumu-
lation and depletion under cultivation and also from the sum 
of its subpopulations, defined by morphology. the kinetic 
curves showed that the accumulation and consumption of 
each studied type of cells parallels its transformation into the 
next subpopulations. the depletion of segmented neutrophils 
means its death.
Differentiation plots of Ph+ leucocytes and its subpopula-
tions – lymphocytes, all myeloid cells, granulocytes, and its 
subpopulations, blasts, promyelocytes, myelocytes, metamy-
elocytes, band and segmented neutrophils – were defined, 
calculating the concentration of corresponding cells in sam-
ples and multiplying its fraction (defined by morphology in 
smears) by 106/ml. the cell morphology in smears was as-
sessed as already mentioned. the cellular composition was as-
sessed in smears in 3 zones of 100 cells each. It should be noted 
that besides morphology Ph+ cML cells № 1.1 and № 2.6 were 
identified by cD antigens expression according to [39], where 
the results of identification and kinetics of cells according to 
both antigen expression and morphology are given and re-
sults are shown to be coincident [33, 39].
Kinetic plots of P/D efficiency. P/D of granulocytes in Ph+ 
cell cultures was defined as the P/D efficiency index that is 
the rate ratio of accumulation and depletion of proliferating 
cells (P cells sum) and neutrophils matured without divid-
ing (D cells sum) under Ph+ mononuclear cells cultivation as 
defined above.
the P/D efficiency index was defined as the ratio of P 
cells (proliferation rate) and D cells (differentiation rate). It 
is equivalent to the ratio between the concentration of these 
cells, according to consideration VP /VD =KP [P] t / KD [D] t 
=KP/ KD x[P] / [D], where VP and VD are the rates of P and D 
cells accumulation; KP and KD, constants of rate; and [P] and 
[D], cell concentrations. KP/ KD = К is the constant of relative 
P/D efficiency.
RESuLTS
In order to study the differences in P&D in the Ph+ cell cul-
tures of patients with different cML phases, we obtained ki-
netic plots for 34 samples of Ph+ mononuclear cells from the 
PB and BM of 23 cML patients under cultivation in strictly 
identical conditions. Ph+ mononuclear cells from PB and BM 
contain hematopoietic cells capable of self-renewal at P&D 
and to P&D for 2-3 cycles, forming the full set of Ph+ cells 
[33, 39].
the majority of mononuclear cells in cML are leucocytes 
[1, 7]; thus, we considered them as Ph+ cells. the leucocytes 
subpopulations include granulocytes, lymphocytes, mono-
cytes; the granulocyte subpopulation contains myeloid pre-
cursors (blasts), promyelocytes, myelocytes and mature  neu-
trophils: metamyelocytes (MM), band (B), and segmented (S) 
neutrophils.
the characteristics of Ph+ cells and corresponding cML 
patients are given in tables 1-3. In cell samples obtained un-
der cultivation, we obtained the kinetic plots of cML leuco-
cytes proliferation and death and differentiation of Ph+ gran-
ulocytes subpopulations: blasts, promyelocytes, myelocytes, 
MM, B and S. In the same samples, we also assayed plots for 
apoptosis and distribution of Ph+ cells in the cell cycle phases 
(Fig. 1-4). the experiments showed a typical for cML ele-
vated granulocytes content [1, 6, 14]. the shape of the plots 
indicates the rate of production or accumulation of the cor-
responding cell type, their transformation to next subpopu-
lations, and final death. thus, the resulting plots reflect the 
main differentiation processes (Fig.1-4 and tables.1-3). the 
leucocytes differentiation coincides with known cML data 
[1-3, 21, 22, 40-42].
Besides the differentiation rate of separate subpopu-
lations (Fig.1-4 a), we studied the plots of overall prolif-
eration and maturation rate. In the 1st case, these were the 
plots of accumulation of P cells differentiating in parallel 
with proliferation and including blasts – myeloid cell pre-
cursors, promyelocytes, and myelocytes. In the 2nd case, 
they were the plots of accumulation of neutrophils – D 
cells: the sum of MM, B, and S matured without dividing 
(Fig.1-4 b).
TyPES OF CML CELLS
Myelopoiesis (P&D of myeloid division of hematopoiesis) be-
gins with the proliferation and differentiation of hematopoi-
etic progenitor cells and their immature progenies. then P&D reSeArcH ArtIcLeS
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continues with neutrophils maturation without dividing [3, 
40, 41]. In this study, we obtained and analyzed ex vivo P&D 
kinetic plots in 34 samples of Ph+ cells from the PB and BM of 
23 cML patients. they demonstrated evident differences in 
the P&D of Ph+ cells from individual cML patients.
the kinetic plots of proliferation and maturation reflect 
the rate of two crucial P&D processes: proliferation with dif-
ferentiation and differentiation without dividing (matura-
tion of neutrophils). the rate ratio of proliferation (P cells ac-
cumulation) and maturation (D cells) reflects the efficiency 
of Ph+ cells proliferation relative to its maturation without 
dividing and is expressed in the P/D index, an indicator of 
P/D efficiency. One can see from the kinetic P and D cell plots 
that the proliferation rate can be higher or lower than that of 
maturation; thus, P&D can give advantage to proliferation 
(effective proliferation) or to maturation (effective matura-
tion). In the first case, the P/D efficiency index P/D1≥1; in the 
second, P/D2 ≤ 1 (Fig.1-4c, tables 1-3).
Table 1. Proliferation and differentiation of types 1 and 2 Ph+ cells in culture
n
Samples of mononuclear cells from PB or BM 
of cML patients Proliferation and differentiation parameters
Sample 
number
cML PB or 
BM
Diagnosis,
treatment 
before 
sampling
type of bcr/
abl rnA,
 leucocytes 
х109/L;
% blasts
P/D,
[immature]/
[mature]
P/D dura-
tion, days
[S]/
[M]
S х106 cells/
ml,  
max/at day
neutrophils
х 106 cells/ 
mlmax /at day
Apoptosis(cell 
death)
% /at day
1 2 3 4 5 6 7 8 9 10
Type 1 Ph+ cells, P/D1 ≥1. Effective proliferation (accumulation rate of immature Ph+ cells is higher than neutrophils maturation rate). Concentration 
[immature] > [mature].
1
1.1
PB cP b3a2 L115;
3 %;
12 - 4
4  - 1
14 0,14 -
0,0 -0,27
0,17 0,53/ 7
-0,32
-0,65/ 14
( 28/ 7
50/ 14 )
2
3
1.2
BM
PB
cP,
Hu*
b3a2
L 72
blasts 3%
1,2 -1,6
2,4 - 1
8
8
0,41
0,5
0,2
0,2 / 3
0,67
0,58 / 3
(33 / 4
30/ 9
4
5
1.3
КМ
PB
AP
chem**
b2a2
blasts 17% 3 – 9
1 – 13
> 8 0,1-0,54
0,1-0,31
0,13 / 8 0,17/ 0-4 (14/ 8 )
6 1.4Blood lymphoidBP,
chem**
b2a2
blasts
30%
>20- 2 > 6 0,0 0/ 0-6 0,4 / 6 (47/ 6 )
7 1.5 PB cP,
Hu*
b3a2
L 175
Blasts 5%
1,2-2,5 < 8 0,14-0,53
0,08 / 4 0,32-0,2
/ 4, 8
(21 / 7)
Type 2 Ph+ cells, P/D2 ≤ 1. Effective maturation ( neutrophils maturation rate is higher than accumulation rate of immature Ph+ cells). Concentration 
[mature] > [immature].
1 2.1
PB
cP→BP
Hu*
b3a2,
L 188-145,
2 %
0,3-0,8 > 6 1,0-1,62
-0.4
0,47/ 2 1,2/ 2 40/ 1
4/ 3
55/ 6
2 2.2 BM
cP
Hu*4 days 
leter
b3a2 0,8-1,5 > 5 0,8-0,4-1,0 0,5 / 2 0,7/1
0,6/5
(4/ 1
11/ 5 )
3 2.3 PB cP b3a2 0,4-1,0 ~ 6 0,4-0,8 0,25/ 3 0,7/3 ( 2 / 3
19 / 7 )
4 2.4
PB
cP, 2 risk 
group, ***
b3a2,
L 165,
blasts 2%
0,3-1, 2 ~ 7 0,73/ 4
2,4/ 8
0,86/ 8 2,4/ 4
1,3/ 8
( 2/ 4
33/ 11)
5 2.5 PB cP b2a2 0,1-1,1-
1,6
~ 7 1,4/ 5 0,7/ 5 1,13/ 5
( 3/ 2
2/ 5
17/ 7 )
6
7
2.6 PB
BM
cP b3a2 0,2-1,0
0,3 -1,0
>9 8/ 6
24/ 11
0,41/ 6 0,7/ 6
0,1/ 11
( 2/ 6
24/ 11 )
8
9
2.7 BM
PB
cP b2a2 1,5
1,5
~ 4-6 -
-
–
-
1,1/ 3
1,3/ 7
(15/1
2/ 2-7
2/ 3
12/ 8 )
The treatment before sampling: *hydroxyurea; **chemotherapy. *** interferon
CP, AP and BP – chronic phase, accelerated phase, and blastic phase – CML phases.112 | ActA nAturAe |  № 3 2009
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In 20% of cML patients, P&D is associated with continu-
ous effective proliferation only. these are type 1 Ph+ cells, 
their P/D1 =1-20 (Fig. 1 b, table 1). P&D of Ph+ cells from 
other cML patients is associated with effective maturation 
only with P/D2 ≤ 1. It corresponds to type 2 Ph+ cells (~30% 
of cases) (Fig. 2 b, table 1). During P&D, these indices vary 
in their limits of P&D. the Figures 1, 2 and table 1 show that 
the continuance of P&D of Ph+ cells types 1 and 2 (7–14 days) 
is comparable with that for 1–2 cell cycles of hematopoietic 
cell clon [3, 40, 41].
the P&Ds of most samples of Ph+ cells are characterized 
by repeated alternations of efficient proliferation and ef-
ficient maturation with the prevalence of the proliferation 
rate and high P/D index (P/D1≥ 1-4), or with the prevalence 
of the maturation rate and low P/D index (P/D ≤ 1) (Fig. 3, 
b, Fig. 4, b and tables 2, 3). these Ph+ cells constitute type 3 
of Ph+ cells. the alternations of proliferation (1st stage) and 
maturation (2nd stage) are clearly identified by crossings of 
the kinetic plots of accumulation of proliferating (P [imma-
ture]) and matureting (D [mature]) cells (Figs.3 and 4b, table 
3). Proliferation and maturation can be accompanied by 1–3 
such alternations that are changing each other according to 
the following schemes: 1/2 -1/2/1 or 2/1-2/1/2, with fre-
quency from 1 to 5 days, rarely 0.2-6 days (tables 3 and 4). 
In alternation according to schemes 1/2 – 1/2/1, the rates 
and, hence, cell concentrations, are changing in the follow-
ing series: [immature] > [mature] → [mature] > [immature] 
→ [immature] > [mature] (Figs.3: 3.1- 3.4, b). In alternation 
according to schemes 2/1 – 2/1/2, the rates and, hence, cell 
concentrations, are changing in the following series: [mature] 
> [immature]→ [immature] > [mature]→ [mature] > [imma-
ture] (Figs.4: 3.10-3.12 ,b). P&D of Ph+ cells type 1 and 2 can 
be considered as a particular case of prolonged alternation of 
proliferation or maturation of Ph+ cells type 3.
At the moment of crossing of effective proliferation and 
effective maturation plots, the alternation of stages, rate of 
Ph+ cells accumulation, and other P&D parameters takes 
place. At the moment of crossing, the proliferation and mat-
uration rates, as well as the indices of their efficiency, be-
come equal. At that moment, P/D = 1.06±0.23 regardless of 
scheme, time point, alternation sequence or cell concentra-
tion (tables 2 and 3). these moments can be called critical 
or equilibrium points. Other characteristics that may be ex-
pected to be equal (concentrations of immature cells, mature 
neutrophils (0.4-0.7х106/ml) and segmented neutrophils only 
(0.1-0.4х106/ml)) in fact were similar (table 3). However, 
the prominent variations (1.53-0.1х106/ml for BM 3.5, PB 
3.10, 3.11 and BM 3.12 in table 3) suggest the concentration’s 
dependence.
During alternations, the cell characteristics are continu-
ously changing (table 2). the parameters increase or de-
crease, passing maximums and minimums. these events are 
usually asynchronous (Fig. 1-4 and table 2). the pattern of 
P/D indices changing depends upon the stage. they vary 
within the limits P/D1 =1-4, P/D2 ≤1. the only exception was 
BM № 3.3, where P/D1 decreased from 11 to 1 3 days before 
it reaches a steady-state and the maturation stage begins. 
under maturation, stage P/D2 varies from 0.1 to 1, untill a 
new proliferation stage with P/D1 >1. It means that the rates 
of proliferation and maturation – their P/D efficiency indi-
ces and concentrations of proliferating and maturating cells 
(especially segmented neutrophils) – are rather significant 
parameters of Ph+ cells P&D.
Analysis of the kinetics of granulocytes subpopulations de-
velopment, the kinetics of apoptosis, and distribution of Ph+ 
cells in the cell cycle phases in combination with differences 
in P/D index and the rates of proliferation and differentiation 
stages of Ph+ cells P&D revealed the following.
Fig.1. Kinetics plots of proliferation and differ-
entiation (as accumulating and consuming) of 
type 1 Ph+ cells subpopulations in the suspen-
sion culture of mononuclear cells isolated from 
bone marrow (BM) or peripheral blood (PB) of 
chronic myeloid leukemia (CML) patients
а – differentiation of granulocytes subpopula-
tions with formation of proliferating myeloid 
precursor cells (blasts), promyelocytes, my-
elocytes, and neutrophils maturated without 
dividing: metamyelocytes, bands, and seg-
mented; b – accumulation and consumption 
of immature proliferating cells, P cells, and 
neutrophiles matured without dividing, D cells, 
as well plots of  proliferation and maturation 
efficiency as ratio of P and D cells accumulation 
rates - P/D index;  c – plots of apoptosis and 
Ph+ granulocyte distribution in the cell cycle 
phases in culture. 1.1 PB – PB Ph+ cells from 
CML CP patient #1.1 before treatment, show-
ing fast progression to CML BP. 1.2 PB and 1.2 
BM – Ph+ cells from CML CP patient #1.2; 1.3 
BM and 1.3 PB – Ph+ cells isolated from patient 
with CML AP under treatment (rapid progres-
sion to blastic phase). Samples characteristics, 
as well as proliferation and differentiation data 
of type 1 Ph+ cell, are shown in Table 1
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Proliferation and differentiation of type 1 Ph+ cells pro-
longed effective proliferation with P/D index >1-2 ÷ 20 
and amount of Ph+ cells in S+G2/M phases ≥ 20-45%; the 
proliferation rate prevails over maturation (Figs.1.2, 1.3.a 
,b, c). P&D is associated with enhanced accumulation of 
myelocytes, promyelocytes, and/or blasts and low accu-
mulation of neutrophils, maturing without dividing (Figs.1, 
a, b,: 1.1-1.3 and 1.4 in table 1) and with a high level of 
apoptosis (Fig.1, c). the lower neutrophils content char-
acterizes the higher P/D index (Fig.1: 1.1-1.3, b) and cML 
progression (table 1). these Ph+ cells were isolated from 
the PB and BM of cML patients at all phases of the disease 
during progression and amounts to one-fifth of all studied 
samples of Ph+ cells.
Table 2. Parameters of alternation for efficient proliferation and efficient maturation stages under condition of  proliferation and differentiation of 3 type 
Ph+ cells in the culture
Item 
№,
Figure     
№
№
ХМЛ
(* )
Parameters of proliferation stage  
Max or interval (days)
 Parameters of maturation stage  
Max or interval (days)    
[S]/
[myelocytes]
Apoptosis 
(death)
%  / at day P/D1
106 cells/ml
P/D2 Min
Max, 106 клеток/мл 
[immature] [mature ]  [S] [[imma-
ture] [mature]  [S ]
Alternation stages according to 1/2 or 1/2/1schemes with changing accumulation rates and Ph+cell concentration   
[immature] >[mature] →  [mature] > [immature] → [immature]  > [mature] 
1,  
Fig. 3
3.1 
 BM
(1/2/1)     
1,4-1,1
1,2-2,3
 
0,35-0,5 
0,64- 0,5
0,29-0,5
0,63-0,2
0,1-0,25
0,3 -0,1
 0,9 
( at 3 day)
0,71 
(at 3 day)
0,8
(at 3 day)
0,4
(at 3 day)
0,5-0,2  5-12
 
2,
Fig.3
3.2**
PB 
(1/2)                
 1,3-1,2 0,4 0,30  0,05 0,85   0,4-0,3  0,53 0,16 0,5 -0,25 < 5
3
4
Fig.3
3.3 
BM
PB (1/2)
11- 2
1,32-1,5
0,6-0,46
0,5-0,8
0,02-0,5
0,4-0,5
0,01-0,4
0,14 -0,25
0,1
1,0-0,2
0,5-0,1
0,5-
0,1
 
0 ,6 
(3 day) 
0,6
 (7 day)  
0,4-0,2
0,3-0,2
 0,1-2,5
 
0,1-1-2,5
(7 at 11  
day)
5
 Fig.3
3.4
BM 
(1/2/1)
1,2
1,53
0,4-0,8-0,5-
1,1
0,34 0,17  0,52-0,34 0,57-0,34 1,1     0,7 0,4-1,3-2 (18 at 5 day)
 
6
  
3.5
BM
(1/2) 
3,43-1,0  1,95        1,65 0,03-
0,37  
1,0-0,3 1,53-0,4 1,53-1,21 0.37-0,5
 
0,19- 0,25-2,0  (30 at 
11day)  
7
   
3.6
BM
(1/2)
1,61 0,61 0,52 0,24 0,28  0,13-
0,56
0,52  -0,4-
0,6
0,24 0,13 -0,5-1,0   (22 at 11 
day)
8
9
3.7
BM (1/2)
PB (1/2/1)
2,5-1,4
2,2-1,2 
1,2-1,4
0.65-0,60
0,51-0,54
0,38-0,32
 0,55
0,5 -0,54
0,4-0,2
 0,3
0,05-0,19
0,15-0,07    
0,7-0,4     
0,78 
 
0,55 
0,57- 0,38 
0,83   
0,73
 
0,53 
0,27 
0,1-0,5 (30 -35 at 
10-11 day)
10
3.8
BM (1/2)  3,9-1,5 0,53-0,35  0,14-0,35 0,02-0,22 1,5-0,5 0,35-0,23 0,35-0,44 0,2-0,4 0,04-0,3 (45 at 7 day)
Alternation stages according to 2/1 or 2/1/2 schemes with changing accumulation rates and Ph+ cell concentration:  
[mature] >  [immature] → [immature] > [mature]→ [mature ] > [immature]  
  
11,
Fig.4
3.10*
PB
(2/1)↔
1,4 -3,1-2,0  0,3-0,6
-0,4
0,3-0,2
 
0,17-0,25 0,2-0,5 0,13-0,3 0,5-0,8-0,3 0,35-0,7 8,5-0,3 34-22 at 
2-5 days 
12,
Fig.4
3.11
PB
(2/1/2) ↔
1,15-1,63 0,8-0,6  0,6-0,8-0,1
 
0,43-0,3  0,33-1,15
0,75-0,8
0,2-0,8,
0,6-0.8-0,1
0,5-1,3-0,8,
0,8-0,1
0,16-0,75-0,4,
0,39-0,06
1,2-0,2 35 at 1  day,
63 at 4 days
13,
Fig.4
3.12
BM
(2/1/2/1/2)
↔
1,0-1,32
1,0 
0,7-0,78
0,24
0,6 
0,24
0,14-0,35
0,12 
 
0,5-0,7-1,0
1,0-0,8-
1,0
0,6-0,7
0,6
0,2
0,4--0,95
0,6
0,14-0,5
0,34
0,1
0,9-0,2 7, 22 at 6, 
11 days
14
3.13
PB
(2/1)
↔
1,7-2,5  0,39 0,4-0,2   0,2-0,1 0,45-1,7 0,42 0,9-0.4 0,3-0,2 0,9-1-9 (48 at 8 
days)
 15
3.14
BM
(2/1)
↔
1,0-1,34 0,6-0,5 0,4  0,4 - 0,2 1,1-0,7 0,4-1,0  0,4-1,37 0,12-0,92 0,3-1,0  (45 at 5 
days)
Footnote: *alternation scheme; **acceleration phase; BM – bone marrow, PB- peripheral blood;   brackets [ ] show cell concentration; hyphen -  
interval of values on the kinetic plots;  Figure ↔ shows that 1st stages data for alternation 2/1 and  2/1/2/1 are given earlier than that of  2d stages 
according  to the subtitle of the table.114 | ActA nAturAe |  № 3 2009
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Proliferation and differentiation of type 2 Ph+ cells is char-
acterized by low efficiency (index P/D ≤ 1) with the prevalence 
of the maturation rate over the proliferation rate and apoptosis 
blocking. P&D of type 2 Ph+ cells is associated with prominent 
neutrophils accumulation inhibiting the Ph+ cells proliferation 
(Fig.2, table 1). Apoptosis inhibition during neutrophils mat-
uration is not synchronous to myelocytes accumulation and 
induction of apoptosis. the decrease of the P/D index is as-
sociated with neutrophiles accumulation; the increase of P/D, 
with depletion of segmented neutrophils (Figs.2, a b, c; 2.1 – 2.7, 
table 1). the mature neutrophils concentration is significantly 
higher than that of proliferating Ph+ cells.
An important characteristic of proliferation is the distribu-
tion of cells in the cell cycle phases. the kinetic plots of type 
2 Ph+ granulocytes distribution in the S and G2/M phases 
show that their changing during proliferation and matura-
tion depends upon their source – cML patient. Figure .2.1, 2.2, 
c shows that the portion of proliferating Ph+ cells in phases 
S+G2/M ≤ 20-40 %; and in G2/M phase, ~ 15%. Another pro-
liferative index – S/(G2+M) ratio is 1.2. the maximum per-
centage of cells in S+G2/M at day 1 was 43 %; and in S phase, 
~ 30%, rapidly declining to 12%. P/D index at the same time is 
0.6-0.8 (Fig. 2.2 b). the percentage of proliferating types 1 and 
2 Ph+ cells is similar (Fig. 2.2 c and Fig. 1.2 c). But the duration 
of elevated percentage of cells in S+G2/M phases in type 2 
Ph+ cells is shorter than in type 1, where the portion of prolif-
erating cells ≥43% is maintained for nearly 6 days with the S/
(G2+M) ratio ~2.4-2.7 and P/D efficiency 1.2-1.6. In terms of 
P&D of type 2 Ph+ cells, that means the prevalence of matu-
ration over proliferation. under cultivation, the percentage 
of proliferating malignant К562 cells (derivate of cML blastic 
phase) in S+G2/M phases reaches 44±3% with little changes 
in the next 7 days. the S/(G2+M) ratio at that time reaches 
4.4. For comparison with these values, the P&D of type 2 Ph+ 
cells is characterized by a decreased percentage of cells in 
S+G2/M phases (< 20 – 40%) with a shortened duration of 
proliferation (<3 days) and low P/D efficiency ≤ 1 (Figs.2.1 
and 2.2, b, c).
the kinetic plots of type 2 Ph+ leucocytes differentiation 
show ~80% granulocytes content, while the percentage of 
myelocytes is not more than 25%. the percentage of mature 
neutrophils, especially segmented, reaches ~40% (Figs.2.1-
2.5, b and 2.1-2.6 in table 1). During P&D, all neutrophils are 
actively accumulated with little consumption. the maximal 
concentration of segmented neutrophils at times is twice that 
of myelocytes (Figs 2.1-2.5 a, b, c, and table 1), emphasizing 
the role of mature cells (especially segmented neutrophils) in 
the regulation of P&D of type 2 Ph+ cells.
In summary, the population of type 2 Ph+ leucocytes in-
creases by 2-4 times under low P/D efficiency and a prolifer-
ation rate lower than that of maturation. It is associated with 
the accumulation of neutrophils (especially segmented), the 
decrease of the myelocyte content, and apoptosis inhibition. 
It means that the excessive accumulation of neutrophils (due 
to apoptosis blockage) inhibits the proliferation of their own 
precursors and the differentiation of neutrophils (metamy-
elocytes, band and segmented), probably through a feedback 
mechanism.
the ratio [S]/[М] is usually a small value; during prolifera-
tion and differentiation of type 2 cells, it increases, exceeds 
1, and reflects the accumulation of segmented neutrophils, 
synchronous to the decrease of myelocytes accumulation. 
the neutrophils accumulation reaches a maximum at day 2 
or 4 (Fig.2: a, b) that corresponds to a minimum accumula-
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Fig.2. Kinetic plots of formation and transformation of 
type 2 Ph+ cells subpopulations as well as kinetics plots 
of their proliferation and maturation (as accumulating and 
consuming) in the suspension culture of mononuclears 
isolated from bone marrow (BM) or peripheral blood (PB) 
of chronic myeloid leukemia (CML) patients
a-, b-, c- the same as in Fig. 1. 2.1 PB, 2.2 BM, 2.4 PB 
and 2.5 PB – samples of cells from corresponding CML CP 
patients. The prolonged observation didn’t reveal signs 
of CML progression. Samples characteristics, as well as 
proliferation and maturation data of type 2 Ph+ cells, are 
shown in Table 1reSeArcH ArtIcLeS
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tion of myelocytes and low P/D index. Figure 2 a, b shows the 
increase of the P/D index because of D cells concentration 
decrease at day 4.
the content of type 2 Ph+ cells is one-third of all studied 
samples; all of them isolated from cML chronic phase (cP) 
patients. the clinical observation of cML patients with type 
2 P&D shows prolonged life duration in case of successful 
therapy.
Proliferation and differentiation of type 3 Ph+ cells takes 
place as repeated alternation of proliferation (stage 1) with 
maturation (stage 2) and changing of the P/D efficiency in-
dex from P/D1 > 1 to P/D2 ≤ 1 etc. (tables 2 and 3). At the first 
stages of alternation, the myelocytes accumulation under ac-
tiv apoptosis prevails over the accumulation of maturating 
neutrophils. Second stages of alternation are characterized 
by efficient maturation with apoptosis blockage and accu-
mulation of enhanced concentration of neutrophils that in-
hibits further proliferation (Fig. 3, 4 and tables 2 and 3). It is 
accompanied by an inversion of the sequence of neutrophils 
accumulation, as in the P&D of type 2 Ph+ cells (Figs. 2–4 a, b, 
c) considered below.
the transition to the next alternation stage 1 according to 
schemes 1/2/1 and 2/1/2 is associated with apoptosis induc-
tion, depletion of segmented neutrophils, and accumulation 
of immature Ph+ cells. thus, at the crossing of the prolifera-
tion and maturation plots, the effective proliferation changes 
to effective maturation and vice versa; the characteristics 
and parameters of the same (but already passed) stage are 
restored.
the P/D efficiency indices depend upon the alternation 
stage, as discussed above (tables 2 and 3). At the first stages, 
index P/D1 >1; at next stages, P/D2 ≤1.
the alternation of the highly effective proliferation of Ph+ 
cells and relatively ineffective neutrophils maturation results 
in increasing and decreasing P/D efficiency (table 3 and Figs. 
3 and 4). It allows to maintain a moderate efficiency of P&D 
on the whole. It corresponds to alternating changing of type 3 
Ph+ cells parameters (tables 2 and 3). taken together, these 
results mean alternation between the efficient proliferation 
and efficient maturation of the participation of segmented 
and other mature neutrophils in the regulation of type 3 Ph+ 
cells P&D through inhibition of Ph+ cells proliferation at the 
maturation stage. A similar regulation can be seen during 
P&D of type 2 Ph+ cells.
Alternating efficient proliferation and efficient matura-
tion according to 1/2 scheme, beginning from stage 1 (Fig. 
3.6, table 2), have P&D characteristics compatible to type 1 
Ph+ cells. the content of myelocytes and proliferating cells 
in S+G2/M phases increases, > 30-45%, at days 1-2 (Fig. 3), 
while the neutrophils content drops. At stage 2 of alternation, 
the segmented neutrophils concentration increases, the P/D2 
index drops ≤ 1, the myelocytes content drops, and the per-
centage of Ph+ cells in S+G2/M phases becomes ≤25%. At the 
beginning of the next stage 1 – the proliferation stage that 
Table 3. The characteristics of crossings at alternation of proliferation and maturation stages during P&D of type 3 Ph+ cells in culture. See notes to 
Table 2
n
Fig.
n cML 
patient
Stage 
alternation 
scheme
crossings of accumulation rate plots for proliferating [immature] (stage 
1) and maturating cells [mature] (stage 2)
cell concentration in crossings, 106 
cells/ml
time of crossing,
Day
1             2
Stages duration, 
days
1           2
P/D indices in crossing 
points n
1           2           3
Mature and 
immature
1        2
Segmented (S)
1          2
1 Fig.3  3.1 M 1/2/1 2;          3,5 2;           1 ,5
2.5
1,1;        1,2;       - 0,5;     0,65 0,24;      0,34
2 Fig.3 3.2 PB 1/2 2,5;         - 2,5;     >4,5 1,06;         -         - 0,4;        - 0,1;          -
3
4
3.3 BM
PB
1/2
1/2
2,5;       5,5 2,5;        8,5
5,5;        5,5
~ 2;          -          -
1,0;          -          -
0,49;         -
0,53;         -
0,26;        -
0,38;         -
5 Fig.3 3.4 BM 1/2/1 0,2;        6 ~ 0,2;        5,8 1,15;        1,2;          - 0,37       0,8 0,17;     0,58
6 3.5 BM 1/2 5;           - 5;          3 1,0;           -           - 1,53;          - 0.37;          -
7 3.6 BM 1/2 4,5;      - 4,5;       3,5 1,06;         -         - 0,53;         - 0,24;         -
8
9
3.7 BM
PB
1/ 2
1/2/1
2,5;       -
2,5;       8,5
2,5;       8,5
2,5;       8,5
1,5;          -            -
1,2;         1,25;       -
0,53;          -
0,54;      0,4
0,4;           -
0,17;     0,15
10 3.8 BM 1/ 2 5;          - 5;        >2 1,5;            -           - 0,35;       - 0,15;          -
11
Fig.4
 3.10 PB 2/1 ↔ 3;          - 4;           3 1,4;           -         - 0,33;       - 0,3;         -
12
Fig.4
3.11 PB 2/1/2/1
↔
   5,5;     7,5;    11 2;       5,5
0;       3,5
1,15;      1,15;     0,80 0,75;         0,6
0,1
0,43;        0,3
0,06
13
Fig.4
3.12 BM 2/1/2/1/2
↔
4,5;     6;      0 8 1,5;       4,5
0;         2,5
           1
1,05;        1,0;      1,0
          1,0  
0,62;       0,72
0,24;       0,24
0,13;      0,35 
0,11;      0,34
 14 3.13 PB 2/1 ↔  4,0 1;           4 1,7;            -            - 0,4 0,2
15 3.14 BM 2/1 ↔  4,0 1;           4 1,0;            -            - 0,6 0,4
The mean value of P/D efficiency index at crossings of proliferation and maturation rate plots at alternation stages 1 and 2 is 1.06 ± 0.23 (21,7%). BM 
– bone marrow, PB- peripheral blood;   brackets [ ] show cell concentration; hyphen -  interval of values on the kinetic plots;  Figure ↔ shows that 1st 
stages data for alternation 2/1 and  2/1/2/1 are given earlier than that of  2d stages according  to the subtitle of the table.116 | ActA nAturAe |  № 3 2009
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happened at day 7 – the percentage of cells in the S+G2/M 
phases again begins to increase (Fig. 3.1 c) and other param-
eters of stage 1 restore. the alternation of stages 1 and 2 is 
analogous to the P&D of Ph+ cells types 1 and 2, correspond-
ingly, but their duration is shorter. the overall duration of 
stage 1 of Ph+ cells type 3 is 4-5 days – 3 times as much as in 
its stage 2 (table 3).
the second stage of alternation of the P&D of type 3 Ph+ 
cells – Ph+ cells corresponds to P/D2≤1 values, high segment-
ed neutrophils concentrations, apoptosis block, and minimal 
concentration of myelocytes (Fig. 4 a, b, c and № 3.10-3.14 in 
table 2). under apoptosis induction and decrease of segment-
ed neutrophils concentration, accumulation of myelocytes 
and the P/D1 index again begin to increase. the maximums of 
P/D1 and myelocytes accumulation coincide with minimum 
segmented neutrophils concentration at day 5. the mature 
neutrophils accumulation leads to a drop in P/D1, decrease 
of myelocytes concentration, and establishment of the effi-
cient maturation stage. these properties are coherent with 
the characteristics of the P&D of type 2 Ph+ cells and other 
patient cells with P&D type 3, according to the 2/1/2 alterna-
tion scheme (Fig. 4 a, b, c; other samples data in table 2).
Inhibition of apoptosis and myelocytes proliferation by 
segmented neutrophils is clearly seen in Figures 3 and 4 a, b, 
c, etc. in table 2. At the same time, the more active the Ph+ 
cells proliferation and apoptosis, the higher is the P/D1 index 
(for example, Fig.3 a, b, c, and table 2).
the distinctive feature of type 3 Ph+ cells P&D according 
to the 2/1/2 scheme, beginning with stage 2, is in a prompt 
and significant accumulation of segmented neutrophils at the 
beginning of P&D and in prominent apoptosis blocking, espe-
cially Ph+ cells proliferation inhibition and distortion of matu-
ration. the apoptosis rate reaches a maximum at 2-5 days and 
equals ~35% (Fig.4, a-c), corresponding by P&D time to the 
depletion and complete death of segmented neutrophils. At 
the beginning, maximum cell proliferation at the maturation 
stage is due to the accumulation and depletion of segmented 
neutrophils; the second maximum of Ph+ cells proliferation 
is already observed due to transition to the efficient prolif-
eration stage after the death of segmented neutrophils (Fig.4: 
3.10, c).
the percentage of cells in particular cell cycle phases for 
2/1 and 2/1/2 alternations is also linked to segmented neu-
trophils accumulation and corresponds to a decreased cell 
number in S+G2/M phases. In Figure 4, a-c, one can see max-
imums at day 1 ~10% (Fig.4: 3.10 BM), ~25 % (3.11 PB), and 
less than 5% (3.12 BM). At days 2-10, the portion of this pool 
significantly decreases. under the next short proliferation 
stage at days 10-11, it slightly increases with a simultaneous 
increase of the P/D1 index. taken together with the decrease 
of P/D2, it means the inhibition of Ph+ cells proliferation by 
neutrophils, more prominent with a more frequent alterna-
tion of prolonged maturation stages.
Figures 4: 3.12, a-c indicate that under alternation of 
2/1/2/1 stages inhibition of proliferation proceeds with P/
D2 = 0.1-0.9. under these alternations, the cell number in the 
S+G2/M phases is 5 % lower for eleven days. At low prolif-
eration at the maturation stage, the apoptosis rate is less than 
10%; at days 6-11, it increases only to 20% and only at the 
transition to stage 1. Overall, the time Ph+ cells № 3.12 stay 
under the effective maturation stage is three times longer 
than at stage 1. It leads to the most prominent inhibition of 
proliferation and apoptosis in type 3 Ph+ cells. In Figures 4: 
3.11 a, b, c, maximum apoptosis corresponds to minimum 
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Fig.3. Kinetic plots of proliferation and maturation of 
type 3 Ph+cells with alternating efficient proliferation and 
efficient maturation stages according to 1/2 or 1/2/1 
scheme in the suspension culture of mononuclear from 
BM or PB of CML patients
a-, b-, c- the same as at Fig. 1. Ph+cell 3d type 3.1 BM, 
3.2 PB, 3.2 BM, 3.3 BM and 3.4 BM – samples of cells 
from corresponding CML CP patients. Parameters char-
acteristics of efficient proliferation and efficient matura-
tion for this Ph+ cell type are shown in Tables 2 and 3reSeArcH ArtIcLeS
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segmented neutrophils accumulation, maximum myelocytes 
accumulation, and P/D index rise. type 3 of P&D was found 
in ~50% of the Ph+ cells studied (all from cML chronic phase 
patients). Among them, 2/3 constitute Ph+ cells with alterna-
tion of 1/2 and 1/2/1 stages.
Apoptosis block segmented neutrophils accumulation and 
inhibition of Ph+ cells types 2 and 3 proliferation by neu-
trophils during effective maturation. the maturating neu-
trophils differentiate in the sequence M→MM→B→S with 
consequent apoptosis of segmented neutrophils. the accu-
mulation of maturating neutrophils decreases in the order 
S>B>MM [3]. If the transport of neutrophils to other tissues 
is impossible, they should die by apoptosis; therefore, the ob-
served prominent S accumulation means the block of apop-
tosis.
the maturation of Ph+ cells type 2 and at 2nd alternation 
stages of Ph+ cells type 3 is associated with apoptosis block-
age, elevation of mature neutrophils concentration, inhibition 
of myelocytes accumulation and decrease of the percentage 
of cells in S+G2/M and/or shortening of their staying in those 
phases. these events explain the inhibition of proliferation by 
neutrophils with blocking of apoptosis. It should be noted that 
apoptosis induction is usually observed under depletion of 
cytokines in cultural media [16-18, 25, 26, 29, 43-45]. During 
maturation stages of P&D for Ph+ cell, apoptosis is blocked 
without addition of cytokines in cultural media.
At S concentration ~2-3х105 cells/ml and high S+G2/M 
cells content, the apoptosis rate is low (<5-10%); at day 5, it 
hardly reaches 10% (Fig. 2.2 a,c). cell death in other cases (by 
trypane blue staining) is also inhibited. In cases 2.2-2.4 BM 
and 2.6 PB, the apoptosis level didn’t exceed 10-20% (table 
1). As one can see in Figure 2.1 a, c, at day 1 of proliferation, 
the maximum apoptosis level reached 40% and 60% at day 
6 with synchronous increase of myelocytes accumulation. It 
means that inhibition of myelocytes accumulation depends 
upon apoptosis blocking not directly but is rather mediated 
by the neutrophils accumulating due to the lack of apopto-
sis.
During P&D of type 2 Ph+ cells, segmented neutrophils are 
even capable of accumulating with a separate peak at days 
2-6 (with [S] > 0,2-0,3х106/ml), as can be seen in Figures 2 a, 
b. It corresponds to a low apoptosis level and minimum myelo-
cytes accumulation (Figs. 2.1 b, c). the myelocytes accumula-
tion plot is broken for the period of significant S accumulation 
(with a maximum at day 2), while the P/D index decreases. 
Myelocytic proliferation is inhibited until the segmented neu-
trophils concentration decreases due to apoptosis. After the 
death of a significant part of S, the pattern of myelocytes ac-
cumulation restores and the P/D index increases (Figs. 2.1 b), 
but it remains ≤1. the maximum of S accumulation (Figs. 2.1 
a, b, c) at days 1 and 5 also corresponds to the minimum of 
myelocytes accumulation, lowering of P/D, and activation of 
apoptosis. A similar S accumulation (at days 2-5) inhibits my-
elocytes accumulation and decreases P/D, as can be seen in 
Figures 2.5 a, b. the death of S at day 5 restores the increase 
of myelocytes concentration and P/D value. Figures 2.2 a, b 
show that maximum S accumulation corresponds to mini-
mum accumulation of myelocytes; i.e., maximum inhibition 
of myelocytes accumulation. At the same time, maximums 
of myelocytes accumulation and apoptotic activity in Figures 
2.1 a, b, c coincide. the same rule applies during P&D of type 
3 Ph+ cells.
thus, the low P&D efficiency of Ph+ cells type 2 and type 
3 at stages of effective maturation leads to prominent neu-
trophils accumulation, decrease of the proliferation rate, in 
comparison with the maturation rate, and decrease of of Ph+ 
cells proliferation. Inhibition of Ph+ cells proliferation by neu-
trophils takes place under alternation of all stages of effective 
maturation and means the participation of neutrophils in the 
regulation of Ph+ cells P&D.
the regulation of P&D Ph+ cells types 2 and 3 consists of 
interdependent synchronous and asynchronous processes. 
Apoptosis inhibition with accumulation of neutrophils, ma-
turing without dividing, proceeds asynchronously to my-
elocytes accumulation, apoptosis induction, and increasing 
efficiency. Myelocytes accumulation is synchronous with 
apoptosis induction, proliferation activation, and increase of 
P/D efficiency.
Inversion of mature neutrophils accumulation order. neu-
trophils maturing without dividing (D cells) by definition 
differentiates in the order M→MM→B→S with consequent 
apoptosis of S [3, 40, 41, 45]. under an equal differentiation 
rate, it can be estimated to have the same order of accumula-
tion. In some cases – at P&D of type 1 Ph+ cells and effective 
proliferation stages in type 3 Ph+ cells – this order is actually 
observed.
During alternation at maturation stages of Ph+ cells types 
2 and 3, maximum and minimum values in the kinetic plots 
of neutrophils accumulation point to a change of their ac-
cumulation order (Figs. 2, 3 and 4, a). It means that the ac-
cumulation rate of S, B and MM changes nonuniformly, and 
that their accumulation order is inverted. At that time, the 
accumulation of myelocytes decreases adjacent to the cor-
responding neutrophils peaks. Moreover, the order of neu-
trophils accumulation from the same Ph+ cells inverts during 
the maturation process, restoring after the transition to pro-
liferation stages.
Figure 2, a shows that order changes with increase or de-
crease of the neutrophils accumulation rate are frequent. It 
can be illustrated by the crossings of the neutrophils accu-
mulation order plots with the inversion of their direction. For 
example, the order M>B>MM~S, visible at day 1, consequen-
tially inverts to S >MM~B>M at day 2, to M>B~S>MM at 
day 3, and to M>MM>S>B at day 6. In this figure the equal 
neutrophils accumulation rates after the crossing of plots at 
days 4-5 leads to an almost normal neutrophils accumula-
tion order – M>>MM>S≥B. In Figure 2:2.1, b one can see the 
usual accumulation order – M>MM>B>S – at day 0, but the 
inversion of this order leads to M>S>B~MM at day 1, then 
to M>>MM>S>B at day 4, and later to S accumulation with 
depletion of M, MM, and B. In Figure 2:2.4, a nearly equal ac-
cumulation rates of 3rd neutrophils at day 4 (M>B~S~MM) 
and at day 8 result in S>>M>B>MM. In Figure 2:2.5, a, ac-
cumulation order M>S>MM>B at day 2 transforms into 
S>M>>MM~B at day 5.
these results mean that the inversions of accumulation 
order, i.e. accumulation rate of neutrophils as a whole and 
their fractions, are frequent. the restoration of the usual 
neutrophils accumulation order corresponds to the increase 
of myelocytes content and P/D efficiency index and promotes 118 | ActA nAturAe |  № 3 2009
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the transition to effective proliferation. rate change and in-
version of neutrophils accumulation order, synchronous to 
the decrease of P/D efficiency index (Figs. 1 and 4, d; 2, 3 and 
4, b), points to the direct participation of neutrophils in the 
P&D regulation of Ph+ cells types 2 and 3 with inhibition of 
their proliferation.
under maturation stage of Ph+ cells type 3 with alter-
nation according to schemes 1/2, 1/2/1 in Figure 3, a the 
inversion of the accumulation order manifests as transfor-
mation from M>MM>S>B to M>S>MM>B and then again 
to M>MM>S~B. At alternations according to schemes 2/1 
and 2/1/2, the inversion of neutrophils accumulation order 
is seen in Figure 4, a. the neutrophils concentrations are de-
creasing in row [S]>>[M]>[B]>[MM], as well as P/D index 
(Fig. 4, b).
thus, there is inversion of order for consequent neu-
trophils maturation with their maximum neutrophils accu-
mulation, whose initial order of neutrophils maturation is 
able to restore by transition to the alternation of the efficient 
proliferation stage. the extent of this inversion and restora-
tion of the neutrophils accumulation order depends upon the 
duration of maturation and proliferation stages. Inversion of 
the accumulation order of M, MM, B, and S is another inter-
esting property of Ph+ cells types 2 and 3 in culture. the rate 
and extent of neutrophils accumulation is changed: at first it 
is S; then, B and MM.
under effective maturation, the neutrophils accumulate 
in significant quantities due to apoptosis blocking (Fig. 2). 
they participate in the regulation of Ph+ cells types 2 and 3 
P&D not only by inhibiting Ph+ cells proliferation, but also by 
inhibiting neutrophils maturation. Inhibition of neutrophils 
differentiation in Ph+ cells types 2 and 3 is revealed at inver-
sion of the initial neutrophils accumulation order with the 
increase in their concentration (Fig. 2, 3 and Fig. 4, also in ta-
bles 1-3). Inversion of the initial neutrophils accumulation or-
der leads to gradual change of the neutrophils accumulation 
sequence M>MM>B>S to S>B>MM>M, and the increase of 
their concentration in the same order is assumed to proceed 
by a feedback mechanism. the present inversion of the ac-
cumulation order and increase of neutrophils concentration 
obviously are the result of a stepwise inhibition of the differ-
entiation of every type of neutrophils (by a feedback mecha-
nism) and consequently leads to their accumulation during 
differentiation of B and MM and, therefore, to inhibition 
(regulation disturbance) of neutrophils maturation. In other 
words, S accumulation inhibits the maturation of B, and it in 
turn inhibits MM maturation. Finally, all neutrophils matu-
ration orders are inhibited, increasing their concentration. 
At the same time, neutrophils inhibit Ph+ cells proliferation 
and P&D efficiency. the next step, after reaching the “criti-
cal” neutrophils concentration, is characterized by apoptosis 
induction. It releases neutrophils from feedback, restores the 
initial neutrophils accumulation order, after which their con-
centration decreases, leading to restoration of the regulation 
of neutrophils accumulation, leading to increase of the P/D 
efficiency index and transition to effective proliferation of 
Ph+ cells.
The role of proliferation and maturation alternation. the 
alternation of effective proliferation and maturation with 
proliferation inhibitions that have different efficiencies and 
provide rate advantage to either the proliferation or matura-
tion of neutrophils adds periodicity to this process. efficient 
proliferation and myelocytes accumulation are synchronous 
to apoptosis induction, elevation of P/D1 >1, but are asyn-
chronous to neutrophils accumulation, inhibition of prolifera-
tion by them, inversion of the neutrophils accumulation order 
and changes of P/D2 within ≤ 1 (Fig. 2-4, tables 1-3).
It should be noted that in the regulation of Ph+ cells P&D, 
both synchronous and asynchronous processes could be ob-
served. the apoptosis inhibition with neutrophils accumula-
tion without dividing proceeds asynchronous to myelocytes 
accumulation and apoptosis induction. Myelocytes accumu-
lation is synchronous to apoptosis induction, proliferation 
activation with increase of P/D index, and to restoration of 
maturation and proliferation regulation.
At the crossing points, P&D parameters equalize. During 
types 1 and 2 Ph+ cells P&D, its regulation at a given differ-
entiation cycle becomes “irreversible.” Modification of type 3 
Ph+ cells properties is reversible: during stages alternation the 
properties inhibited at the previous stage can be restored. By 
P&D regulation the type 3 Ph+ cells seems to be more “nor-
mal” than type 1 or 2. All types of Ph+ cells probably depend 
upon the inherited properties of the bcr/abl gene in different 
cML patients. Of note, the P&D regulation of Ph+ cells in all 
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Fig.4. Kinetics plots of proliferation and maturation of subpopulations 
of 3d type Ph+cells that perform by alternating efficient proliferation and 
efficient maturation stages according to 2/1 or 2 /1/2 schemes in the 
suspension culture of mononuclears from  BM or PB of CML patients. 
Parameters and characteristics of efficient proliferation and efficient matu-
ration of this Ph+ cell type, are in table 2 and 3reSeArcH ArtIcLeS
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three types of Ph+ cells from different cML patients differs in 
the quantitative characteristics of P/D efficiency, apoptosis 
inhibition, S accumulation, and the extent of Ph+ cells prolif-
eration inhibition. under P&D of Ph+ cells types 1 and 2, its 
P/D efficiency indice  varies in the limits P/D1 >1 or P/D2 
≤ 1, correspondingly (Fig. 1 and 2, table 1). It points to some 
extent of P&D regulation of Ph+ cells in limits P/D1 >1 or P/
D2 without changing the initial advantage of the proliferation 
or maturation rate.
the differences in P&D regulation are related to the prop-
erties of Ph+ cells from different cML patients at different 
phases of the disease. evidently, P&D efficiency is deter-
mined by myeloid cell precursors in Ph+ mononuclear cells 
fraction, inheriting the mutations in bcr/abl gene and p210 
tyrosine kinase from different cML patients. the mutations 
capable of determining carcinogenicity in Ph+ cell lines, cell 
viability, activity of proliferation, and apoptosis blockage are 
studied in [7, 17, 18, 25, 27, 29, 30].
the alternation of Ph+ cells proliferation and maturation 
ex vivo with the rise or fall of P&D efficiency participates in 
the regulation and maintenance of an optimum regimen of Ph+ 
cells P&D. under apoptosis blocking, it alternately switches in-
hibition of proliferation by maturing neutrophils, especially S, 
being the progeny of the same proliferating Ph+ cells. the cell 
regulation by segmented neutrophils probably mediates ge-
netic regulation with participation of the bcr/abl gene. these 
results are concordant with evidence for the separate trans-
forming and antiapoptotic activity of different mutant forms 
of р210 bcr/abl tyrosine kinase in cell lines that change signal 
transduction pathways [8, 9, 15,17, 18, 20, 27, 30, 31].
As a result, alternation of effective proliferation and ef-
fective maturation with the change of increased efficiency 
indices to very low ones leads to a fall in the overall P&D ef-
ficiency of Ph+ cells types 2 and 3 and, thus, maintains a mod-
erate, possibly optimum P&D regimen. At maturation stages, 
P&D regulation is mediated by the increase of neutrophils 
(especially S) content, proliferation inhibition with a decrease 
of P/D efficiency indices, and inversion of the neutrophils 
maturation order in Ph+ cells types 2 and 3.
DISCuSSION
the elicited P&D regulation in Ph+ cells ex vivo reveals the 
cellular aspects of genetic P&D regulation. As was shown in 
the present work, cellular regulation is mediated by alterna-
tion of Ph+ cells proliferation with efficient maturation and 
is accomplished by proliferation inhibition by maturating 
without dividing neutrophils – progenies of the same pro-
liferating Ph+ progenitor cells under conditions of apoptosis 
blockage.
the cellular regulation of hematopoietic cells P&D and its 
proposed mechanism had previously never been considered 
in the literature [4-7, 9-12, 15, 16, 21- 23, 27, 30]. there was 
no data on the cellular regulation of Ph+ cells P&D by mature 
neutrophils and on the alternation of stages with high and 
low P&D efficiency until this study. Also, there was no data 
on the relative proliferation and maturation rate, their effi-
ciency, and its quantitative equivalent (P/D index). the ratio 
of proliferating hematopoietic cells and mature neutrophils in 
single PB samples was designated previously as the matura-
tion index [2].
the proliferation of myeloid progenitor cells and the initial 
stage of Ph+ cells P&D regulation had been extensively stud-
ied [4,5,7, 8,10-12, 15,16, 20, 23-25, 26]. It is determined by the 
proliferative potential and concentration of cD34+ myeloid 
progenitor cells. Activation of Ph+ cells proliferation depends 
upon bcr/abl oncogene expression, its mutations, and higher 
rate of Ph+ stem cells transition from G0 to G1 cell cycle phase 
in comparison with cells without Ph chromosome [20, 23, 24]. 
regulation of Ph+ cells proliferation is characterized to some 
extent (by the kinetic method of P&D investigation) also in 
our study. It is clear from the P&D parameters of type 1 Ph+ 
cells and alternations with effective proliferation stages in 
Ph+ cells type 3. the studies [33, 39] have shown the partici-
pation of cD34+ myeloid progenitor cells and bcr/abl expres-
sion in Ph+ cells from PB sample № 1.1, studied here in P&D 
regulation of type 1 Ph+ cells. According to this, a maximum 
level of cD 34 antigen and bcr/abl expression is coincident 
with a high, efficient P/D index at the beginning of Ph+ cells 
P&D.
the study [28] on Ph+ cells from cML cP patients isolated 
by flow cytometry has shown a direct relationship between 
myeloid Ph+ progenitors and bcr/abl oncogene expression. 
the authors have established a decrease in the proliferating 
Ph+ cells fraction in S+G2/M phases – by 4 times for myelo-
cytes and by 7 times for B and S in comparison with cD34+ 
cells. A direct linear correlation of the Ph+ cells fraction in 
S+G2/M phases and bcr/abl expression was seen in cD34+ 
cells, myeloblasts, and promyelocytes. But later in the course 
of differentiation, the correlation inverted. It means, that 
active accumulation of proliferating Ph+ cells in S + G2/M 
phases at the beginning of the proliferation stage is propor-
tional to the rise in bcr/abl expression, while during P&D 
from myelocytes to B and S this proportionality inverses. In 
this study we didn’t estimate kinetic parameters. the data 
used was obtained from a single probe of each of the 15 cML 
cP patients. Our results provide a good explanation of this 
correlation inversion in study [28] by a change in the mecha-
nism of Ph+ cells proliferation due to inhibition of Ph+ cells 
proliferation by the neutrophils accumulating under apop-
tosis blockage.
taken together, the work of Primo et al [28] and our study 
indicate the paradoxical mechanism of bcr/abl action on Ph+ 
cells. the expression of bcr/abl in proliferating myeloid Ph+ 
progenitors activates proliferation, but later mature Ph+ neu-
trophils that inherit the same oncogene bcr/abl inhibit pro-
liferation. In other words, the promoting proliferation effect 
of bcr/abl oncogene expression in Ph+ cells at early stages of 
P&D is inhibited by the expression of the same oncogene in 
the progenies of the same Ph+ cells at later stages of matura-
tion. It can be explained, for example, by the change in the 
signal transduction pathways by bcr/abl oncogene, p210 ty-
rosine kinase, and spectrum of StAt proteins formed in the 
neutrophils or in one of them.
Some studies propose an alternative hypothesis on the 
development and progression of cML, considering the im-
balance of stem cells self-renewal and further cell differen-
tiation, rather than the activation of proliferation due to un-
controlled expression of р210 bcr/abl, as the main cause of cML 
[20-24,13-14, 26]. It is associated with a decreased number of 
cML progenitor cells, while their progenies in cML are more 120 | ActA nAturAe |  № 3 2009
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abundant in comparison with that in “normal” cells. Distor-
tion of Ph+ cells maturation as a primary biological defect 
in cML was discussed elsewhere rather long ago [13,14,21, 
22, 42]. the example of Ph+ cells types 2 and 3 P&D in our 
work shows that such an imbalance is mediated by the neu-
trophils inhibiting Ph+ cells proliferation at maturation stage 
under apoptosis blockage. the revealed differences in P&D 
regulation with inhibition of proliferation by neutrophils with 
apoptosis blockage and alternation of efficient proliferation 
and efficient maturation of Ph+ cells from different patients 
inheriting different bcr/abl mutations completely explain 
the contradictions regarding the imbalance of Ph+ cells self-
renewal and maturation.
Proliferation inhibition by neutrophils during the alterna-
tion of proliferation and maturation under apoptosis block-
age is assumed to regulate also P&D of hematopoietic cells 
in normal conditions. In cML, this mechanism can possibly 
be an attempt by cML cells to escape proliferation activa-
tion by bcr/abl expression, leading to cML progression. the 
threat of cML progression can be seen, for example, at P&D 
of type 1 Ph+ cells under apoptosis induction and absence of 
neutrophils excess.
CONCLuSIONS
1. the P&D regulation of Ph+ cells from different cML pa-
tients is performed by alternation of effective proliferation 
with effective maturation. In the maturation stage, the Ph+ 
cells proliferation is inhibited by accumulating neutrophils 
with apoptosis blockage interrupting proliferation and main-
taining the optimum P&D level.
2. the alternation of stages consists in the switching of 
stage 1 – effective proliferation – when the proliferation rate 
of Ph+ cells exceeds that of maturation, to stage 2 – effective 
maturation – when apoptosis is blocked, and the neutrophils 
maturation rate is higher than the proliferation rate. the al-
ternation can proceed according to the schemes 1/2 -1/2/1 or 
2/1-2/1/2. the alternation stages have control points where 
its plots cross and the indices of proliferation and maturation 
are equal. the indices of P/D efficiency (ratio of proliferation 
and maturation rates) at control points are equal to 1.06±0.23 
and don’t depend upon time and alternation order, as well as 
the source of Ph+ cells – cML patients. In alternation stages, 
these indices are permanently changing.
3. In the proliferation stages, the proliferating cells content 
rises, the number of neutrophils (especially S) decreases and 
apoptosis is activated. In the maturation stages, on the con-
trary, apoptosis is blocked, the neutrophils content (especially 
S) is enhanced, while the number of immature is decreased. 
In the effective maturation stage, accumulating neutrophils 
inhibit the proliferation of immature Ph+ cells and the order 
(sequence) of neutrophils maturation is inversed and im-
paired, probably via a feedback mechanism.
4. the differences in P&D regulation allowed us to identify 
3 types of Ph+ cells in cML patients differing by the number 
and duration of alternation stages. there are Ph+ cells whose 
P&D has either one prolonged effective proliferation stage 
or one prolonged effective maturation stage, or multiple al-
ternations of effective stages of proliferation and maturation. 
the first corresponds to advanced cML phases; the other 
takes place in the cML chronic phase with good response to 
chemotherapy.  
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